Dysgeusia News and Research

RSS

Lithium chloride can alleviate radiation-induced oral mucositis and taste dysfunction

Oral mucositis and taste dysfunction (dysgeusia) occurs in nearly all patients receiving head and neck radiotherapy and tremendously affects the quality of life and treatment outcome.

11 Mar 2021

Researchers conduct large meta-analysis of COVID-19’s neurological manifestations

The global spread of the COVID-19 pandemic, caused by SARS-CoV-2, has led to intense interest in the various manifestations of the infection, including its neurological features. A compact summation by researchers across the UK of what is known at present about this facet of the disease is presented in a new paper.

3 Mar 2021

Neuroinvasiveness of SARS-CoV-2 shown by viral RNA and inflammation in the brain

A new study describes the results of a macaque study that showed the development of neurological features of inflammation, following infection by SARS-CoV-2.

25 Feb 2021

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Researchers in Italy report a correlation between the loss of smell and taste and an observed persistence or rise in antibody levels at five months after infection.

9 Feb 2021

Altered smell and taste impacts psychological wellbeing of COVID-19 survivors, study finds

A recent study discloses that loss of taste and smell sensation after infection with SARS-CoV-2 negatively impacts the quality of life and psychological wellbeing of those that recover but experience persistence of this symptom.

1 Dec 2020

Many hospitalized COVID-19 patients exhibit neurological symptoms, study finds

Nearly a third of hospitalized COVID-19 patients experienced some type of altered mental state and function, ranging from delirium to confusion, and in some cases, unresponsiveness, a new study has found.

7 Oct 2020

Smell and taste changes last longer than other COVID-19 symptoms

A preprint paper published on the medRxiv server details a recent study by researchers from The Hebrew University, Hadassah-Hebrew University medical center, and Hadassah University Hospital, which addresses this gap in knowledge about the symptoms experienced by COVID-19 patients.

28 Sep 2020

Loss of taste in COVID-19 is highly variable by geographic region

Even as the COVID-19 pandemic spreads in different parts of the world, scientists are still attempting to define the characteristic signs and symptoms that are useful in diagnosing the disease. This is essential knowledge to help contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. Especially when it comes to diagnosing symptomatic or mild cases of COVID-19, such research could hold the key to identifying more people and preventing viral spread.

15 Sep 2020

A better understanding of SARS-CoV-2 in children

Researchers at Duke University School of Medicine in Durham, North Carolina, have conducted a study showing that Hispanic ethnicity is associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among children.

24 Aug 2020

Internet searches can help track the spread of COVID-19, says UofL researcher

When they're feeling sick, many people turn to the Internet. They Google their symptoms -; headache, chest pain, shortness of breath -; hoping to learn more about what's happening in their bodies.

10 Jun 2020

Olfactory impairment linked with milder clinical course in COVID-19

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization.

27 Apr 2020

COVID19 patients describe a loss of smell and taste

Some medical specialists think that the sudden inability to smell or taste familiar odors and flavors could be an early sign of the novel coronavirus infection. This sign could be as innocuous-looking as feeling that food suddenly tastes bland, or that familiar strong smells aren't getting through. Yet, it could signal the need to isolate oneself because it is a little-known yet characteristic sign of COVID-19, the disease caused by the novel coronavirus that is racing around the world.

23 Mar 2020

FDA approves first therapy for symptomatic tenosynovial giant cell tumor

Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.

3 Aug 2019

FDA approves new treatment for AML patients

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

22 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Dysgeusia News and Research

Lithium chloride can alleviate radiation-induced oral mucositis and taste dysfunction

Researchers conduct large meta-analysis of COVID-19’s neurological manifestations

Neuroinvasiveness of SARS-CoV-2 shown by viral RNA and inflammation in the brain

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Altered smell and taste impacts psychological wellbeing of COVID-19 survivors, study finds

Many hospitalized COVID-19 patients exhibit neurological symptoms, study finds

Smell and taste changes last longer than other COVID-19 symptoms

Loss of taste in COVID-19 is highly variable by geographic region

A better understanding of SARS-CoV-2 in children

Internet searches can help track the spread of COVID-19, says UofL researcher

Olfactory impairment linked with milder clinical course in COVID-19

COVID19 patients describe a loss of smell and taste

FDA approves first therapy for symptomatic tenosynovial giant cell tumor

FDA approves new treatment for AML patients

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News